

Appln No.: 10/605,498  
Amendment Dated: March 30, 2006  
Reply to Office Action of November 30, 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-13. (canceled)

14. (currently amended) A pharmaceutical composition comprising a therapeutic agent effective to reduce the amount of active hsp27 in cancerous cells exposed to the therapeutic agent, and a pharmaceutically acceptable carrier, wherein the therapeutic agent is an oligonucleotide and wherein the oligonucleotide is an antisense ~~oligonucleotide~~ ~~oligonucleotide~~ comprising the sequence of bases as set forth in ~~any one of~~ Seq. ID Nos. ~~81 or to 82, or an siRNA comprising the sequence of bases as set forth in any one of~~ Seq. ID Nos. ~~83-90~~.

15. (canceled)

16. (currently amended) The composition of claim ~~14 +5~~, wherein the antisense oligonucleotide has backbone modifications to provide resistance against nuclease digestion *in vivo*.

17. (currently amended) The composition of claim ~~14 +5~~, wherein ~~oligonucleotide is an antisense~~ and the oligonucleotide has a length of from 12 to 35 nucleotides.

18. (previously presented) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 81.

19. (previously presented) The composition of claim 14, wherein the antisense oligonucleotide comprises the sequence of bases as set forth in Seq. ID No. 82.

20-24. (canceled)

25. (previously presented) The composition of claim 14, wherein the composition is packaged in dosage unit form.

26. (previously presented) The composition of claim 25, wherein the dosage unit form is an injectable solution.

27. (previously presented) The composition of claim 19, wherein the composition is packaged in dosage unit form.

Appln No.: 10/605,498

Amendment Dated: March 30, 2006

Reply to Office Action of November 30, 2005

28. (previously presented) The composition of claim 27, wherein the dosage unit form is an injectable solution.

29-43 (canceled)